We Remain Open And Committed To Providing Critical Addiction Treatment. Read More Here:  COVID-19 Update

FDA Grants “Fast Track” To Non-Opioid Medication

non-opioid medication | Just Believe Recovery PA

In This Article

FDA Grants “Fast Track” To Non-Opioid Medication

The Food and Drug Administration has designated a new non-opioid medication called tanezumab to be put on “fast track.” The drug is indicated for persons with chronic lower back pain and osteoarthritis. It targets and binds to a protein known as nerve growth factor, which multiplies in the body after injury and inflammation. As a result, pain signals are prevented from reaching the brain.

Tanezumab is the first nerve growth inhibitor to be given this designation. According to the FDA, fast trackfast track is “a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.”

Ken Verburg of Pfizer Global Product Development stated that the company believes that tanezumab will be “an important medical advance” in the treatment of the two painful conditions for patients who “do not experience adequate pain relief or cannot tolerate currently available pain medications.”

Pfizer is joining forces with Eli Lilly in development, and the two drug manufacturers are recruiting 7,000 participants for tanezumab studies in which patients will be injected with the drug once every eight weeks for periods that range from 16-56 weeks. Results are not expected until 2018.

An estimated 27 million persons in the U.S. currently suffer from osteoarthritis, and another 23 million suffer from chronic lower back pain.

In 2010, it was the FDA that delayed development of nerve growth inhibitors due to safety reasons, as a small number of patients needed joint replacements when their disease worsened. The research did not continue until 2015, and Pfizer states current studies include joint and sympathetic nervous system safety measures.

Last year, another nerve growth factor drug called Fasiumab was being developed and studied by Teva and Regeneron Pharmaceuticals, but was also stopped by the FDA after one patient revealed signs of serious joint disease. The companies stated they intended to redesign the study to exclude patients with severe osteoarthritis.

~ G. Nathalee Serrels, M.A., Psychology

Just Believe Recovery Carbondale

Just Believe Recovery is a fully licensed, Joint Commission accredited, comprehensive drug and alcohol treatment center located in Carbondale, Pennsylvania

Have Questions?

🔒 Your information is safe & secure

Sidebar Contact PA

  • This field is for validation purposes and should be left unchanged.
Party Drugs | Are They Addictive? | Just Believe Recovery PA
Abused Substances

Party Drugs: Are They Addictive?

As the name would imply, party drugs (also referred to as club drugs) are substances usually consumed by older teens and young adults at parties,

Read More »